This study investigated whether KMUP-1, a xanthine-derivative K + channel opener, could prevent serotonin-induced hypertrophy in H9c2 cardiomyocytes via L-type Ca 2+ channels (LTCCs). Rat heart-derived H9c2 cells were incubated with serotonin (10 μM) for 4 days. The cell size increased by 155.5%, and this was reversed by KMUP-1 (>1 μM), and attenuated by the LTCC blocker verapamil (1 μM) and the 5-HT 2A antagonist ketanserin (0.1 μM), but unaffected by the 5-HT 2B antagonist SB206553. A perforated whole-cell patch-clamp technique was used to investigate Ca 2+ currents through LTCCs in serotonin-induced H9c2 hypertrophy, in which cell capacitance and current density were increased. The LTCC current (I Ca,L ) increased ~2.9-fold in serotonin-elicited H9c2 hypertrophy, which was attenuated by verapamil and ketanserin, but not affected by SB206553 (0.1 μM). Serotonin-increased I Ca,L was reduced by KMUP-1, PKA and PKC inhibitors (H-89, 1 μM and chelerythrine, 1 μM) while the current was enhanced by the PKC activator PMA, (1 μM) but not the PKA activator 8-Br-cAMP (100 μM), and was abolished by KMUP-1. In contrast, serotonin-increased I Ca,L was blunted by the PKG activator 8-Br-cGMP (100 μM), but unaffected by the PKG inhibitor KT5823 (1 μM). Notably, KMUP-1 blocked serotonin-increased I Ca,L but this was partially reversed by KT5823. In conclusion, serotonin-increased I Ca,L could be due to activated 5-HT 2A receptor-mediated PKA and PKC cascades, and/or indirect interaction with PKG. KMUP-1 prevents serotonin-induced H9c2 cardiomyocyte hypertrophy, which can be attributed to its PKA and PKC inhibition, and/or PKG stimulation.
Introduction
Cardiac ventricular hypertrophy is a hallmark of progressive heart failure. Increased myocardial mass characteristic of the compensatory ventricular remodeling process is mainly attributed to hypertrophy of individual cardiomyocytes [1] . This process is initiated by a variety of stimuli, including paracrine and
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International Publisher endocrine factors such as catecholamines, angiotensin II, endothelin, growth factors and inflammatory cytokines [2] . Additionally, serotonin (5-hydroxytryptamine, 5-HT) is believed to play a role in the regulation of cardiac growth in pathological conditions. Previous reports showed higher blood 5-HT levels in heart failure patients, which may be due to either clearance defect or enhanced secretion [3, 4] . Moreover, chronic treatment of 5-HT in rodents causes cardiac hypertrophy as well [5, 6] .
5-HT receptors are widely expressed in the cardiovascular system. In the heart, converging evidence shows that 5-HT2A receptor expression and function are greatly altered during cardiac remodeling, supporting its role in the development of cardiac hypertrophy and failure. In rodent models of heart failure, a novel ventricular inotropic responsiveness to 5-HT appears, which is mediated in part through the 5-HT2A receptor [7] . In addition, the 5-HT 2A receptor is upregulated in human heart failure [7] and 5-HT 2A receptor blockade reverses hypertrophy during pressure overload in a mouse model of increased 5-HT levels [8] . 5-HT 2A receptors trigger a hypertrophic response by 5-HT stimulation, through the involvement of transient receptor potential canonical 1 (TRPC1) channels [9] and calcineurin/NFAT activation [1] .
5-HT has even been shown to increase the magnitude of the L-type Ca 2+ current (I Ca,L ) in human atrial myocytes via 5-HT 4 receptors [10] , which may contribute to intracellular calcium overload and arrhythmic activity. The 5-HT 4 receptor is functionally present in the human atrium but not in the ventricle [11] . The present study used the H9c2 cell line, initiated by Kimes and Brandt (1976) , established from spontaneous beating embryonic rat cardiac ventricle. Kimes and Brandt addressed that the beating activity ceased after the third "selective serial passage" [12] . This H9c2 cell line has properties similar to neonatal and adult cardiomyocytes [13, 14] . After undergoing differentiation, these cells can functionally express L-type Ca 2+ channels (LTCCs) and ATP-sensitive K + channels [13, 15] . Until now, the possible mechanism of serotonin-increased I Ca,L has never been well described in H9c2 cells. We designed this study to determine whether protein kinases (i.e. PKA, PKC and PKG) are involved in the cascade of serotonin-induced rat heart-derived H9c2 cell hypertrophy model, using functional and electrophysiological studies.
A xanthine-derivative KMUP-1 has been demonstrated to increase cyclic nucleotides and stimulate K + channels, resulting in relaxation in aortic, corporeal cavernosa and tracheal smooth muscles [16] [17] [18] , and to activate BK Ca channels [19] and inhibit LTCCs [20] in rat basilar artery myocytes. KMUP-1 was found to inhibit monocrotaline-induced chronic pulmonary arterial hypertension via cGMPdependent inhibition of ROCK and modulation of K + channels [21] . It also attenuates isoprenaline-induced cardiac hypertrophy through the NO/cGMP/PKG pathway [23] . We have proved that it might have value in the management of cerebral vasospasm after subarachnoid hemorrhage [24] . However, it is not known whether KMUP-1 can modulate the influx of Ca 2+ through LTCCs in H9c2 cardiomyocytes. The main objectives of this study were to characterize the role of protein kinases in serotonin-induced H9c2 cell hypertrophy and to elucidate the mechanisms by which KMUP-1 prevents 5-HT-induced ventricular myocyte hypertrophy via LTCCs mediated signaling pathways.
Materials and methods

Cell culture
The H9c2 cardiomyocyte-like cell line (ATCC CLR-1446; Rockville, MD) derived from rat embryonic myoblasts is commonly used as an in vitro model of cardiomyocyte biology [12, 14] since it shows similar hypertrophic and apoptotic responses as those seen in primary adult and neonatal cardiomyocytes [25] . Cells were plated onto collagen-coated culture dishes and cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) in a humidified atmosphere of 5% CO 2 and 95% air at 37 o C. Cells were used under the 20 th passage.
Serotonin-induced cell hypertrophy
H9c2 cells were performed under serum-free medium (DMEM with 0.1% FBS) and plated onto 6-cm dishes and stimulated with serotonin (1, 10 µM) for 4 days to measure their changes in cell surface area. Cell images were viewed with a digital camera fixed to a microscope (Nikon). The H9c2 cell surface area was analyzed for at least 30 cells per condition using the public ImageJ 1.47 software. To understand the mechanism of serotonin-induced H9c2 hypertrophy, the cells were exposed to the LTCC blocker verapamil (1 μM), the 5-HT2A antagonist ketanserin (0.1 μM) and the 5-HT 2B antagonist SB206553 (0.1 μM) for 4 days. KMUP-1 was also applied in this experiment to observe its preventive effects on serotonin-induced H9c2 hypertrophy.
Patch-clamp electrophysiology
To measure the I Ca through L-type Ca 2+ channels [20, 26] , perforated whole-cell patch-clamp electrophysiology was used in rat heart-derived H9c2 cells. In brief, H9c2 cells treated with or without serotonin were detached with 0.25% trypsin-0.02% EDTA solu-tion, the supernatant removed by centrifugation, and the pellets resuspended in 1 ml of bath solution containing (in mM): 135 tetraethylammonium (TEA)-Cl, 1.8 CaCl 2 , 2 MgCl 2 , 10 glucose, and 10 HEPES, (pH 7.4, Tris) using a fire polished glass pipette. The cells were put in a recording dish and then perfused with a bath solution. To minimize outward potassium currents, Cs + rather than K + was used in the pipette solution. A recording electrode was pulled from borosilicate glass (resistance: 3-5 MΩ), and the pipette was coated with sticky wax close to the tip to reduce capacitance and backfilled with pipette solution containing (in mM) 140 CsCl, 1 EGTA, 1 MgCl2, 5 Na 2 ATP, and 5 HEPES (pH 7.2, Tris). Nystatin (300 µg/ml) was included in the pipette solution for the perforated patch-clamp recordings. Serotonin-treated cells were clamped at -80 mV and depolarized to 0 mV for 300 ms to evoke whole-cell I Ca . Voltage clamped cells were equilibrated for 15 min prior to experimentation. Membrane currents were recorded on the MultiClamp 700B amplifier (Molecular Devices Corporation, Sunnyvale, CA), filtered at 1 kHz using a low-pass Bessel filter, digitized at 5 kHz and stored on a computer for subsequent analysis with Clampfit 10.2. A 1 M NaCl-agar salt bridge between the bath and the Ag-AgCl reference electrode was used to minimize offset potentials. All electrical recordings were performed at room temperature. Following equilibration, serotonin-increased ICa was monitored in the presence and absence of KMUP-1 (0.1, 1, 10 µM). To ascertain whether PKA, PKC or PKG signaling was involved in the KMUP-1-inhibited I Ca in serotonin (10 µM)-treated H9c2 cells, the activators and inhibitors of PKA (8-Br-cAMP, 100 μM and H89, 1 µM), PKC (phorbol 12-myristate 13-acetate (PMA), 100 μM and chelerythrine, 1 µM) and PKG (8-Br-cGMP and 100 μM, KT5823, 1 µM) were added in perfusate for this purpose.
Chemicals
Buffer reagents, chelerythrine, H-89, PMA, serotonin, TEA-Cl and verapamil were obtained from Sigma Aldrich Chemical Co. (St. Louis, MO). 8-Br-cAMP, 8-Br-cGMP, KT5823, ketanserin and SB206553 were obtained from Tocris Bioscience (Bristol, UK). All drugs and reagents were dissolved in distilled water unless otherwise noted. Chelerythrine, KT5823 and PMA were dissolved in DMSO at 10 mM. Serial dilutions were made in phosphate buffer solution with a final solvent concentration <0.01%.
Data analysis and statistics
Data were expressed as means ± SE; n indicates the number of cells. A repeated measure ANOVA was used to compare values at a given voltage. When appropriate, a Tukey-Kramer pairwise comparison was used for post hoc analysis. p values <0.05 were considered statistically significant.
Results
Effects on serotonin-induced H9c2 cells hypertrophy
Exposure of H9c2 cardiomyocytes to serotonin (1, 10 μM) caused time-dependent increases in cell surface area, an indicator of cell hypertrophy, and produced a marked hypertrophic response at day 4 ( Fig. 1) . Serotonin-induced H9c2 cell hypertrophy was significantly reversed by co-incubation with KMUP-1 (1-10 μM). Under the same situation, the LTCC blocker verapamil (1 μM) and the 5-HT2A antagonist ketanserin (0.1 μM) also significantly attenuated the hypertrophic responses induced by serotonin, but not the 5-HT 2B antagonist SB206553 (0.1 μM) (Fig. 2) . 
Cell capacitance and current density in serotonin-induced hypertrophic cells
The cell capacitance in serotonin-induced H9c2 cell hypertrophy (81.6±3.3 pF, n>30) was larger than that of the control cells (serotonin-free; 65.0±3.8 pF, n>30, p<0.05, Fig. 3A) . Data also showed significant increases in LTCC current density in hypertrophic H9c2 cells (2.1±0.3 pA/pF, n>30) compared to the control cells (0. 7±0.1 pA/pF, n>30, p<0.001, Fig. 3B ).
Effects on I Ca,L in serotonin-induced hypertrophic cells
Perforated patch-clamp was used to study the effect of I Ca,L increases in serotonin (10 μM)-induced H9c2 cell hypertrophy. Depolarizing single pulse (0 mV for 300 ms) was applied from a hold potential of -80 mV to record the inward I Ca,L current. Serotonin induced significant H9c2 cell hypertrophy and enhanced the I Ca,L ~2.9-fold control at day 4. The increased I Ca,L of hypertrophic H9c2 cells was inhibited by co-incubation with KMUP-1 (0.1-10 μM) in a dose-dependent manner. This current was also inhibited by co-treatment with verapamil (1 μM, ~60%) or ketanserin (0.1 μM, ~40%), but unaffected by SB206553 (0.1 μM) in hypertrophic H9c2 cells (Fig. 4) .
Increased I Ca,L involved PKC activation in serotonin-induced hypertrophic cells
To determine whether PKC plays a role in serotonin-increased I Ca,L , the PKC activator PMA and inhibitor chelerythrine were used in this experiment. The possible mechanisms of KMUP-1 protection against serotonin-increased I Ca,L were also examined. We monitored the I Ca,L of serotonin (10 μM)-induced H9c2 hypertrophic cells in the presence of 1 μM chelerythrine, 1 μM KMUP-1, 1 μM PMA or 1 μM PMA plus 1 μM KMUP-1 for 4 days. As shown in Fig. 5 , the PKC inhibitor chelerythrine abolished the increased I Ca,L and the PKC activator PMA significantly enhanced this current in hypertrophic H9c2 cells. Enhanced I Ca,L from serotonin plus PMA was also abolished by KMUP-1 co-incubation.
Increased I Ca,L involved PKA activation in serotonin-induced hypertrophic cells
To ascertain the role of PKA in serotonin-increased I Ca,L and KMUP-1's effects on this current, the PKA activator 8-Br-cAMP and inhibitor H-89 were used. We monitored the I Ca,L of serotonin (10 μM)-induced H9c2 hypertrophic cells in the presence of 1 μM H-89, 1 μM KMUP-1, 100 μM 8-Br-cAMP or 100 μM 8-Br-cAMP plus 1 μM KMUP-1 for 4 days. The PKA inhibitor H-89 alone inhibited the control current ~25%. The PKA activator 8-Br-cAMP combined with serotonin did not further enhance the ICa,L current, and this effect was abolished by KMUP-1. Serotonin-increased I Ca,L was attenuated by H-89 or KMUP-1 (Fig. 6) .
Increased I Ca,L involved PKG inhibition in serotonin-induced hypertrophic cells
To determine whether PKG is involved in serotonin-increased I Ca,L and KMUP-1's effects on this current, the PKG activator 8-Br-cGMP and inhibitor KT5823 were used. We monitored the I Ca,L of serotonin (10 μM)-induced H9c2 hypertrophic cells in the presence of 100 μM 8-Br-cGMP, 1 μM KT5823, 1 μM KMUP-1 or 1 μM KT5823 plus 1 μM KMUP-1 for 4 days. The PKG activator 8-Br-cGMP attenuated the ICa,L in hypertrophic H9c2 and control cells, but the PKG inhibitor KT5823 showed no significant effects in both cells. KMUP-1 inhibited serotonin-increased I Ca,L which was partly reversed by KT5823 (Fig. 7) . * P<0.05, *** P <0.001 compared with control.
## P <0.01, ### P <0.001 compared with the serotonin group.
✝ P <0.001 compared with the serotonin+8-Br-cAMP group. Data are means ± SE, n=8.
* P<0.05, *** P <0.001 compared with control.
# P <0.05, ### P <0.001 compared with the serotonin group.
✝ P <0.005 compared with the serotonin+KMUP-1 group.
Discussion
This study is the first to use patch-clamp electrophysiology to investigate the role of PKA, PKC and PKG in serotonin-induced H9c2 cardiomyocyte hypertrophy and to examine the protective mechanisms of KMUP-1 against cardiomyocyte hypertrophy. Serotonin induced H9c2 cell hypertrophy, which increased cell size and ICa,L, was reversed by the K + channel opener KMUP-1, attenuated by the LTCC blocker verapamil and the 5-HT 2A antagonist ketanserin, but unaffected by the 5-HT 2B antagonist SB206553. We also found that serotonin-increased I Ca,L was reduced by the PKA or PKC inhibitor and the PKG activator, and was enhanced by the PKC activator but not affected by the PKG inhibitor. Interestingly, while KMUP-1 blunted serotonin-increased I Ca,L , this was partly reversed by the PKG inhibitor. In light of our results, we suggest that serotonin increases I Ca,L mainly by activating the 5-HT 2A receptor-mediated PKA and PKC cascades, and partly by interacting with PKG. KMUP-1 prevents serotonin-induced H9c2 cardiomyocyte hypertrophy primarily by PKA and PKC inhibition and/or PKG stimulation.
Previous reports have demonstrated that H9c2 cell membranes expressed cardiac and skeletal types of LTCCs. The difference between the Ca 2+ current of cardiac and skeletal muscle is related to different mechanisms of depolarization-contraction coupling [14, 27] . Hescheler et al. (1991) also pointed out that H9c2 cells show morphological characteristics similar to immature embryonic cardiomyocytes but preserve several elements of the electrical and hormonal signal pathway found in adult cardiac cells. This cell line may be useful as a model for cardiomyocytes in terms of transmembrane signal transduction. To understand H9c2 cardiomyocyte hypertrophy, cardiac ICa,L was our target in this study. Therefore, we suggest that serotonin-induced hypertrophy in H9c2 cells provides advantages to understand the progression of pathogenic myocardial hypertrophy in humans.
A previous report showed that 5-HT2A receptors mediate the receptor-dependent hypertrophic activity of serotonin in cardiac cells. The role of these receptors in cardiac hypertrophy has been supported by various results in vivo. In a mouse model of increased plasma serotonin, 5-HT2A but not 5-HT 2B receptors were involved in pressure overload hypertrophy [8] .
Other studies also showed that 5-HT 2A receptors mediated positive inotropic response in ventricular myocytes and were overexpressed in different models of cardiac hypertrophy, along with human heart failure [7, 28] . Additionally, 5-HT 2A receptor blockade reverses hypertrophy during pressure overload and reduces left ventricular hypertrophy [8, 29] . 5-HT 2B receptors have also been implicated in ventricular hypertrophy. It has been shown that 5-HT 2B receptors on cardiac fibroblasts mediate the release of IL-6 and indirectly induce cardiomyocyte hypertrophy [30] . In this study, serotonin-increased cell size and I Ca,L were not affected by the pharmacological (SB206553) blockade of 5-HT 2B function, which suggested that 5-HT 2B receptors could not have an important role in H9c2-mediated hypertrophy.
In the present study we extend previous in vivo findings that KMUP-1 was observed to prevent isoprenaline-induced cardiac hypertrophy via activation of NO/cGMP/PKG and inhibition of ERK1/2/calcineurin A signaling cascades [23] . Increased cGMP production prevents cardiac hypertrophy has not been entirely elucidated but it probably involves PKG. PKG inhibits LTCCs thus reducing Ca 2+ influx and blocking calcineurin-mediated activation of nuclear factor of activated T cell (NFAT), a transcription factor that is obligatory for hypertrophy [23, 31] . This study not only assessed the role of PKG but also PKA and PKC in 5-HT-induced H9c2 cardiomyocyte hypertrophy. Data obtained from patch-clamp recordings, we suggest that PKC plays a major role whereas PKA or PKG plays a relatively minor role in 5-HT-induced H9c2 hypertrophy. This work attempted to explain the connection of 5-HT receptors and intracellular protein kinases in H9c2 hypertrophy induced by serotonin. Another possible hypertrophic mechanism for 5-HT transporter (SERT) needs to be investigated further [1, 32] .
To our knowledge, this report is the first to describe the relationship between serotonin-increased ICa,L and the transduction pathway of protein kinases in hypertrophic H9c2 cells using patch-clamp recordings. The novel finding of this report is that serotonin increased the I Ca,L currents, a marker of cell hypertrophy, which was attenuated by PKA and PKC inhibitors (H-89 and chelerythrine) and enhanced by the PKC activator PMA. Serotonin-mediated I Ca,L effects were also reduced by the PKG activator 8-Br-cGMP, but unaffected by the PKG inhibitor KT5823. Thus, we suggest that serotonin-induced H9c2 hypertrophy can be directly attributed to 5-HT 2A receptor-mediated PKA and PKC pathways, indirectly interacting with PKG. The K + -channel opener KMUP-1 reversed or blunted serotonin-mediated cell hypertrophy and I Ca,L currents, and therefore its mechanism of action could be due to the modulation of these intracellular cascades of protein kinases (Fig.  8) . Previously, we have demonstrated that KMUP-1 inhibits Ca 2+ entry via voltage-dependent LTCCs in rat basilar arteries, which is attributed to its modulation of the PKC pathway [20] . In this study, the single concentration of protein kinase inhibitors/activators and receptor antagonists used are considered for their selectivity and specificity [33] .
In summary, this study presents evidence that PKA and PKC play a key role in regulating serotonin-mediated cell hypertrophy and I Ca,L changes via activation of 5-HT 2A receptors in H9c2 cardiomyocytes. This investigation is also the first to use patch-clamp electrophysiology to study KMUP-1 prevention of serotonin-induced cardiomyocyte hypertrophy by blocking PKA-and PKC-mediated Ca 2+ influx through LTCCs, and by stimulating PKG-inhibited Ca 2+ influx. Finally, we suggest that KMUP-1 could be of value in controlling cardiac hypertrophy due to serotonin overstimulation under pathophysiologic conditions. 
